View allAll Photos Tagged immunization
Dr. Pascal Villeneuve of UNICEF, the chair of the Inter-Agency Health Donors Group (GIBS), emphasized the need for the government of DRC to continue to commit financial resources toward reaching unvaccinated children.
Dr Pascal Villeneuve de l’UNICEF, Représentant du Groupe Inter Bailleurs de Santé (GIBS) a insisté sur le besoin du Gouvernement de la RDC de continuer à mettre les ressources financières disponibles pour atteindre les enfants non vaccinés.
Photo by Kaukab Jhumra Smith/USAID
There have been no new cases of wild polio virus in the Democratic Republic of Congo since December 2011, a marked contrast from a high of 100 cases in 2010. World Immunizations Week, April 24 to 30, 2015, presented an opportunity to celebrate this exciting public health milestone and offered a chance to commit to reaching all the children who have not yet been vaccinated against preventable diseases. USAID contributes $3.5 million each year to polio vaccination efforts in the DRC through the World Health Organization (WHO), UNICEF and USAID’s Integrated Health Project. USAID also supports immunizations worldwide through direct support to GAVI, the Vaccine Alliance.
On April 28, 2015, in Mbankana, Kinshasa province, USAID officials joined the Prime Minister of the DRC, Augustin Matata Ponyo, the DRC Minister of Health, Dr. Felix Kabange Numbi, and representatives from GAVI and other international donors, at a ceremony at a newly built health center. The event honored DRC’s efforts to remain polio-free and launched a fleet of new refrigerated trucks for the safe transport of vaccines to remote areas of the country.
To reach a home of a 4-year-old P.Otgonjargal. Ms Oyunchimeg’s team traveled by jeep, reindeer, a rope-drawn ferry and foot. A team member examines the girl, who is accompanied by her mother. © UNICEF/NYHQ2012-1732/BRIAN SOKOL
Nasra Mohammed Sherifwith her 7 months child - Siham Mohammed after getting polio vaccine at Togwajale Health Center, Jigjiga, Somali Regional State ©UNICEF Ethiopia/2019/Nahom Tesfaye
Rotary International advocacy visit to Ethiopia to support the polio eradication efforts and participate in the National Polio Immunization campaign in November 2014, where nationally, over 13 million children under the age of five will be vaccinated against polio. ©UNICEF Ethiopia/2014/Tsegaye
British Rotarians take immunize children in the streets of Lucknow during a round of the polio immunization campaign in Northern India. .Rotarians Bernice Yates, Pam Joyce and Jackie Berry work at a polio vaccination booths on the first day of the campaign..The drive is part of the campaign to eradicate polio in India and target the high-risk area of Uttar Pradesh and Bihar. (photo Jean-Marc Giboux)
(Karen Kasmauski/MCSP). General scenes in the Maternity center at Tsafe General Hospital where immunizations, family planning, pre-and post natal care as well as birthing by midwives.
Isonail Kabiru, rt. and Badiru Halidu, are Male motivators who go into the community and talk to the men about family planning.
Official Launch of the Polio Sub-NID, at the India Islamic Center in Lucknow, Uttar Pradesh, with Mullana Khalid Rasheed and District Magistrate A.K. Ghosh and visiting british rotarians , on November 8, 2009 . (photo Jean-Marc Giboux)
Rotary International advocacy visit to Ethiopia to support the polio eradication efforts and participate in the National Polio Immunization campaign in November 2014, where nationally, over 13 million children under the age of five will be vaccinated against polio. ©UNICEF Ethiopia/2014/Tsegaye
Noakhali, Bangladesh
The Bede are a migrant group in Bangladesh that have no permanent settlement and go wherever they want to go. Supposedly, the Roma of Europe are descendants from the Bede. As one can imagine, life is very difficult for this ethnic group. Children rarely receive health services or an education, and jobs are always scarce. But the children are like children everywhere, they enjoyed laughing and wanted to know more about their strange-looking visitors.
Premier John Horgan, Adrian Dix, Minister of Health, Dr. Bonnie Henry, Provincial Health Officer, and Dr. Penny Ballem, executive lead for B.C.’s immunization plan, announce that more than 400,000 people in British Columbia will be immunized from March to early April as the Province moves into Phase 2 of the largest immunization rollout in B.C.’s history.
Learn more: news.gov.bc.ca/releases/2021PREM0015-000355
At a maternal and child clinic at La Fossette, one of the largest in Cap-Haitian, patients arrive for regular check-ups as well as vaccinations. Pictured are ward nurses and student nurses giving a baby a regular check-up.
Photo Credit: Karen Kasmauski/MCSP and Jhpiego
www.ama-assn.org/delivering-care/public-health/what-docto...
What doctors wish patients knew about the Novavax COVID-19 vaccine
There’s a fourth COVID-19 vaccine option in town: Novavax. The availability of the Novavax COVID-19 vaccine offers another option for people who may have been hesitant about getting vaccinated. But with its approval so late in the pandemic, some may wonder what distinguishes the Novavax option from other COVID-19 vaccines. Knowing those differences may be a deciding factor for hesitant individuals.
In this installment, Sandra Fryhofer, MD, an Atlanta general internist and chair of the AMA Board of Trustees, discusses the Novavax COVID-19 vaccine. Dr. Fryhofer also serves as the AMA’s liaison to the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) and is a member of ACIP’s COVID-19 Vaccine Work Group.
For primary vaccination only
“We now have a third type of vaccine in the fight against COVID,” Dr. Fryhofer said during an episode of the “AMA COVID-19 Update” about the Novavax vaccine. “A two-dose series of Novavax protein subunit COVID vaccine is now recommended for unvaccinated” individuals who are 12 or older “for primary vaccination against COVID-19.”
But it is important to note that “Novavax has to be used for both doses in the primary series,” she said. “You can't mix and match with a different product or type.”
It’s not new technology
“This vaccine contains harmless spike protein subunits with an adjuvant added to boost immune response. And, unlike mRNA vaccines, protein-based vaccines do not contain any genetic material,” said Dr. Fryhofer. “Our vast experience with protein subunit vaccines should be reassuring to those who worry about the newness of mRNA vaccine technology.”
“This protein-based platform is new for COVID vaccines but it's not really new. This technology has been around for more than 30 years,” she said, noting “it’s already been used in making other vaccines, for example, for flu, hepatitis B and whooping cough.”
Novavax can only be used as a primary series” because the Food and Drug Administration (FDA) “has not authorized it as a booster yet,” said Dr. Fryhofer. “However, there's a lot of interest in the prospect of using Novavax as a booster, especially since mRNA vaccines don't seem to be that durable.”
But Novavax has submitted booster data to the FDA. Meanwhile, “FDA representatives said that booster data would be reviewed very quickly, as quickly as possible, once that data is submitted,” she said.
“The company also announced that it started a study in May looking at Novavax boosters after an mRNA primary vaccine series,” Dr. Fryhofer explained. “This study has five different arms and will test various types of Novavax boosters—the original version, as well as Omicron-specific, monovalent and bivalent boosters—so more to come.
Effectiveness of Novavax is tricky
“The study data submitted to FDA says, overall, it was about 90% effective at preventing COVID,” said Dr. Fryhofer. “However, it did not seem to work quite as well in those 65 and older. Vaccine efficacy in this older group was 79%.
“And for some unexplained reason for which it doesn't make any physiological sense, vaccine efficacy in those of Hispanic ethnicity was also a little lower at 77%,” she added, noting “here’s the catch: The studies submitted to FDA were done before Omicron started circulating.”
Because of that, “we just don’t know how it will work against Omicron,” Dr. Fryhofer said. “The Omicron surge started in December 2021 and still dominates. Omicron's BA.5 sublineage now makes up” 80% and BA.4 makes up a little more than 5% “of specimens tested, and who knows what variant is next on the menu.”
“The Novavax studies were done during a time when the Alpha variant was predominant, and the South Africa study showed that Novavax was only 51% effective against the Beta variant,” she said, adding that “we really can't compare vaccine effectiveness of Novavax to that of mRNA vaccines based on the data that we currently have available.”
Expect typical side effects
“Just like the mRNA vaccines, these vaccines are reactogenic, so expect fatigue, muscle pain, joint pain, headache, maybe some nausea, vomiting, maybe a little fever,” said Dr. Fryhofer. “These side effects usually go away within one to two days.”
“Unfortunately, as we've seen with the mRNA vaccines, there have been reports of myocarditis and pericarditis after Novavax during the clinical trials and also in early post-authorization data,” she said. “We know that the risk of heart complications is higher after COVID disease than after mRNA COVID vaccination among males and females of all ages.
“However, we can't directly compare myocarditis rates between Novavax and mRNA vaccines based on currently available data,” Dr. Fryhofer added. “Now, in the Novavax clinical safety study, there were only four to six cases identified out of more than 40,000 vaccine recipients. “As of the beginning of May of 2022, nearly 750,000 doses of Novavax had been administered in other countries and global post-marketing safety data have revealed 36 cases of myocarditis or pericarditis.”
“Myocarditis risk was addressed by the FDA in its guidance fact sheets, and FDA explains the chance of myocarditis is very low, but it can occur usually within 10 days following vaccination,” she explained. “It also says patients who have chest pain, shortness of breath, the fast heartbeat, heart fluttering or a pounding heart should seek medical care right away.”
“Post-authorization safety monitoring will continue and will be so important in further defining myocarditis risk,” Dr. Fryhofer noted.
Novavax is easy to store and use
“It comes in 10-dose vials, and it's preservative free. A dose is half a cc and contains 5 micrograms of protein subunit antigen along with 50 micrograms of a proprietary adjuvant Matrix-M, which boosts the immune response,” said Dr. Fryhofer, adding it is given “intramuscularly in the deltoid muscle.”
“Novavax has several logistical advantages. It's easy to store, easy to prepare and easy to administer,” she said. “You store it at regular refrigerator temperatures but don't freeze it. No dilutions necessary, but vaccine has to be discarded if it's not used within six hours after the first puncture of the vial.”
You can wait longer between doses
“In the study, vaccine doses were administered three weeks apart. However, CDC guidance says you can extend the interval between doses to as long as eight weeks,” said Dr. Fryhofer. “This extended interval guidance is based on data from mRNA vaccines. There are no specific data on extended intervals for Novavax and this is all based on the mRNA vaccine studies.”
“Some studies of mRNA vaccines have indicated a lower risk of myocarditis and greater immune response with that extended interval,” she said. “The eight-week interval could be considered, especially in young adult males, to reduce potential for myocarditis and at the same time optimize vaccine effectiveness.
“This extended interval recommendation does not apply to those with immunocompromised conditions,” Dr. Fryhofer added. “CDC recommends sticking to that three-week interval for patients with immunocompromised conditions so we can get their immune protection built up as quickly as possible.”
Be mindful of vaccine coadministration
There’s some “good news” about coadministration of flu and COVID-19 vaccines, said Dr. Fryhofer. “It's fine to give flu shots and COVID vaccines at the same time, and that also goes for the Novavax vaccine.
“Also, there's no problem giving Novavax or any of the other COVID vaccines with other vaccines with one exception: orthopoxvirus vaccines,” she added, noting that while “we're in the middle of a monkeypox outbreak … ACAM2000 and JYNNEOS are the two vaccines available for orthopoxvirus viruses.”
Unfortunately, “ACAM2000 has been linked to myocarditis. We don't know if there's an increased risk of myocarditis with JYNNEOS yet, but if you've received a dose of one of these orthopox vaccines, CDC suggests waiting four weeks to get a COVID vaccine dose,” Dr. Fryhofer explained. “However, if you've already received a COVID vaccine and you're now at risk of monkeypox due to exposure, no need to wait. Go ahead and get the monkeypox vaccine dose now.
“And remember, Novavax and other COVID vaccines are reactogenic and can have significant side effects,” she said. “The shingles vaccine—Shingrix—also is very reactogenic, so you might want to think twice about getting both shingles vaccine and COVID vaccine on the same day.”
time.com/6208623/omicron-boosters-animals-clinical-trials/
Omicron Boosters Are Coming, But They Weren’t Tested on People. Here’s What You Need to Know
With nearly all the new COVID-19 infections in the U.S. coming from the Omicron BA.4 and BA.5 subvariants, it makes sense that health officials are considering switching to a different vaccine to protect the public.
White House COVID-19 response coordinator Dr. Ashish Jha expects the first Omicron-specific booster to be available in mid-September at the earliest, if the U.S. Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) authorize and recommend the shot. In late August, both Pfizer-BioNTech and Moderna submitted requests to the FDA for authorization of their Omicron-specific boosters.
But with the fall and winter fast approaching—the seasons when respiratory viruses like SARS-CoV-2 spread even more efficiently, as students return to school and people huddle indoors—getting the booster ready requires a more efficient review and regulatory process. And that includes considering safety and efficacy data from animals, not people.
Back in June, the FDA’s panel of independent vaccine experts met to consider switching the country to a new booster that targets Omicron, given how quickly that variant is dominating new infections. At the time, the two largest COVID-19 vaccine makers, Pfizer-BioNTech and Moderna—which both make mRNA-based vaccines—had developed shots against an earlier Omicron variant, BA.1. The panel decided that if health authorities were going to change the booster shot to target Omicron, the next one should protect against the BA.4 and BA.5 subvariants, which would continue to account for almost all cases in the winter season.
They asked the vaccine manufacturers to develop a new vaccine, one that combined the original vaccine and also targeted Omicron BA.4 and BA.5. At the end of August, both companies submitted data on their new, bivalent vaccines to the FDA for emergency use authorization.
Given the short time they had to develop the shot, however, the data only included information on the safety and efficacy of the booster in animals. Human studies are planned and will be ongoing even if the FDA and CDC decide to authorize the shots and the government starts distributing them. The FDA has also decided to review the animal study data without consulting its advisory committee again.
That has vaccine experts divided. Dr. Paul Offit, a member of the advisory committee, says this strategy makes him “uncomfortable” for several reasons. He notes that the data presented from Pfizer-BioNTech and Moderna in June involving their BA.1 booster shot, which focused on the levels of virus-fighting antibodies the vaccine generated, were underwhelming. “They showed that the neutralizing antibody titers were between 1.5- and two-fold greater against Omicron than levels induced by a booster of the ancestral vaccine,” he says. “I’d like to see clear evidence of dramatic increase in neutralizing antibodies, more dramatic than what we saw against BA.1, before launching a new product. We’re owed at least that.”
While conducting human studies does take more time, Offit says even a small trial involving about 100 people to measure their antibody levels after getting a BA.4/5 booster would be helpful. “You can boost people and measure their neutralizing antibodies two weeks later,” he says. Such information could also be critical in setting realistic expectations for the Omicron booster. The public might feel it’s a panacea that signals the end of the pandemic, but without any data showing how well the booster will protect people from not only getting sick, there might be unrealistic expectations about what the boost can do. “I get a little nervous, frankly, when I hear this [booster] is going to be miraculous,” Offit says.
Other experts see it a little differently. Based on the fact that the mRNA vaccines have been administered to millions of people so far, with relatively few safety concerns, and given that the vaccines have been effective in protecting people from getting hospitalized or dying of COVID-19, even during the latest Omicron surges, they argue that changing the strain of virus in the vaccine doesn’t require the same extensive testing that the original shot did. “The totality of evidence is relevant here,” says Dr. Ofer Levy, director of the precision vaccines program at Boston Children’s Hospital, and also a member of the FDA’s vaccine advisory committee. “We are in a situation where we need to pivot as variants emerge, and if we try to be too rigid in our approach, we will always be behind, and not giving the population optimal protection.”
Levy says that the latest Omicron-specific boosters that the FDA is considering contain a combination of mRNA targets against both the original virus and Omicron BA.4/BA.5, so the data on safety and efficacy from the original vaccine in protecting against hospitalization and death is relevant. While the data on this vaccine does come from animals, using that data to decide whether or not to authorize the booster is a matter of “hedging bets.” There is data showing that even vaccinated and boosted people can get mild to moderate COVID-19 disease, because their vaccine-induced protection is waning, so boosting with a shot that is better matched to the Omicron subvariants circulating now is a reasonable bet, even if the data on its efficacy comes from animals and not people. “I think it’s the right decision,” says Levy.
There’s no guarantee that the FDA will authorize the new bivalent vaccines, although all signs point to an authorization that could come in a week or so. If the shots are released and people get boosted, health officials will be carefully monitoring data from those vaccinees to ensure that the assumptions they made about the safety and efficacy of the booster hold. And hospitalization rates in the coming winter will reveal whether betting on the new Omicron-specific booster was the right decision.
Pilot in Mali for MenAfriVac immunization campaign.
If you wish to use this photo, please credit WHO.
Photo: WHO.
Ampoules containing doses of Coronavac, immunized against covid-19, are seen in a thermal box at a health center set up for the vaccination campaign at the Manaus Convention Center, Amazonas, Brazil, on February 25, 2021. The City of Manaus continues with the vaccination campaign of health professionals from the day January 19th. Health professionals are receiving the Coronavac immunizer (produced in partnership with Sinovac, from China, with the Butantan Institute, from Brazil).
The state of Amazonas experienced, between January and February this year, a collapse of its health system caused by the high number of infections by covid-19, the lack of beds and oxygen in the health units.
IMF/ Raphael Alves
25 February 2021
Manaus, Amazonas, Brazil
Photo ref: 20210225_f&d-54.jpg
Bru Burger Bar was located in a renovated Greyhound bus station. While remodeling the old station they found lost and found items that tols a story from the early days of the bus station. An old wallet and its photographs, licenses, immunization cards, etc. Rather than throw them out, they had them framed and can be seen along the stairs leading to the upper floor (where an original window and some tiles can be seen)
HERAT, 6 October 2015 – Some 300,000 children are being immunized against polio in two of Afghanistan’s western provinces as part of a UN-supported campaign to combat the crippling disease.
Following concerns about an outbreak from a new polio case in Herat, the Ministry of Public Health, together with the United Nations Children Fund (UNICEF) and World Health Organization (WHO), commenced an immunization campaign throughout Farah and Herat.
“The emergence of a polio case in the Shindand district of Herat can be a threat, and if we don’t act on an emergency basis, children in some vulnerable areas could be affected by the virus,” said Ahmed Shah Ahmedi, a UNICEF official.
Mr. Ahmedi explained that the three-day vaccination campaign follows on the heels of a nationwide programme, launched earlier this year, that vaccinated children in all districts across the western regions.
Wahid Rahmani, the coordinator of the anti-polio programme at Herat’s Directorate of Health, said insecurity in different areas of the country and movement of individuals and families from the south to the western provinces have contributed to the spread of the virus.
This year, health officials have identified 12 new cases of polio throughout the country. Of these, five were in the western region: four in Farah and one in Herat.
According to WHO, polio remains endemic in only two countries – Afghanistan and Pakistan – with the eradication of polio globally depending primarily on stopping the disease in these countries.
Photo: UNAMA/Fraidoon Poya.
Nasra Mohammed Sherifwith her 7 months child - Siham Mohammed after getting polio vaccine at Togwajale Health Center, Jigjiga, Somali Regional State ©UNICEF Ethiopia/2019/Nahom Tesfaye
As the Ebola outbreak worsens in Liberia, many children have missed routine immunizations. Star of the Sea, a Catholic clinic in Monrovia, Liberia, is one of the few clinics that remains open and provides immunizations and other routine health services. Photo by Michael Stulman/CRS
Catholic Relief Services has committed more than .5 million in private funds to continue its emergency response to the Ebola outbreak in West Africa. The number of deaths and people infected with the virus continues to increase rapidly. CRS and its Caritas partner have been working to train more than 400 volunteers on key messages about Ebola as well as psychosocial counseling for those who've lost loved ones to the disease. Education is the only way to stop the spread of the disease, so CRS has been working on public awareness campaigns aimed at teaching the population about Ebola, including its spread and prevention.
HERAT, 6 October 2015 – Some 300,000 children are being immunized against polio in two of Afghanistan’s western provinces as part of a UN-supported campaign to combat the crippling disease.
Following concerns about an outbreak from a new polio case in Herat, the Ministry of Public Health, together with the United Nations Children Fund (UNICEF) and World Health Organization (WHO), commenced an immunization campaign throughout Farah and Herat.
“The emergence of a polio case in the Shindand district of Herat can be a threat, and if we don’t act on an emergency basis, children in some vulnerable areas could be affected by the virus,” said Ahmed Shah Ahmedi, a UNICEF official.
Mr. Ahmedi explained that the three-day vaccination campaign follows on the heels of a nationwide programme, launched earlier this year, that vaccinated children in all districts across the western regions.
Wahid Rahmani, the coordinator of the anti-polio programme at Herat’s Directorate of Health, said insecurity in different areas of the country and movement of individuals and families from the south to the western provinces have contributed to the spread of the virus.
This year, health officials have identified 12 new cases of polio throughout the country. Of these, five were in the western region: four in Farah and one in Herat.
According to WHO, polio remains endemic in only two countries – Afghanistan and Pakistan – with the eradication of polio globally depending primarily on stopping the disease in these countries.
Photo: UNAMA/Fraidoon Poya.
More immunizations and a clean bill of health from the vet yesterday.
14 1/2 weeks old. 7.2 lbs
Posting photos has taken a back seat to raising puppies and going to work these days. But I'm still taking pictures. More to come. We are having a beautiful autumn!
October 13, 2017.
IMG_6883 iPhone
Nasra Mohammed Sherifwith her 7 months child - Siham Mohammed after getting polio vaccine at Togwajale Health Center, Jigjiga, Somali Regional State ©UNICEF Ethiopia/2019/Nahom Tesfaye
Alemnesh Gerefa (mother) with her one year old baby Kedir Mudi, at the Derer Ebija Health Post where they have come to get the newly introduced PCV vaccine.
©UNICEF Ethiopia/2011/Lemma
Severe immune reaction to immunization shots, resulted in a weekend (and ongoing) of 102+ fevers and this gorgeous red welt. Surprisingly, it doesn't itch at all.
(Karen Kasmauski/MCSP). General scenes in the Maternity center at Tsafe General Hospital where immunizations, family planning, pre-and post natal care as well as birthing by midwives.
Photo Credit: Allan Gichigi/MCSP
A child recieves vaccination in a health center in Igembe, Meru Kenya
The 13th Vaccination Week in the Americas (VWA) will be celebrated from April 25th to May 2nd, 2015. The regional slogan for VWA 2015 is “Boost your power! Get vaccinated!” Vaccines are weakened or killed pathogens that help your immune system fight diseases. Vaccines do not make you sick, but prepare your body to fight off disease when exposed to full strength pathogens in the future. Vaccines boost the power of your immune system and fight off more than 20 different vaccine-preventable diseases. To read more on how vaccines boost your power, check out: www.paho.org/vwa/
UNICEF supports a nationwide measles vaccination campaign to protect 15.5 million children from life-threatening diseases. The launch of regional vaccination campaign in Haik town, Amhara region, Ethiopia 27 December 2022. In addition, integrating in the campaign, a range of other lifesaving services. These include COVID-19 jabs and catch-up immunizations for under-vaccinated children, screening for acute malnutrition, vitamin A drops and deworming against intestinal parasites. ©UNICEF Ethiopia/2022/Mulugeta Ayene
Alemnesh Gerefa (mother) with her one year old baby Kedir Mudi, at the Derer Ebija Health Post where they have come to get the newly introduced PCV vaccine. – they wait in turn as Health Extension Worker Shewaye Berhanu administers the vaccine.
©UNICEF Ethiopia/2011/Lemma
The original caption to this Tokyo photo says that city health officials are pictured giving anti-Cholera toxin injections to wives of fishermen. Tokyo was threatened with a great Cholera plague, and drastic measures were taken by health authorities, to halt the epidemic. (Getty Images)
Via:
www.wsls.com/features/2020/12/15/vaccinations-throughout-...
Getting a flu shot each year is the best way to protect you from the flu. The American Pharmacists Association wants you know that getting a vaccine is as easy as visiting your local pharmacist. Stop in or log on to Pharmacist.com/FluShot for information. For More Info: yourupdate.tv/technology/fathersdaytechgifts/
Nasra Mohammed Sherifwith her 7 months child - Siham Mohammed after getting polio vaccine at Togwajale Health Center, Jigjiga, Somali Regional State ©UNICEF Ethiopia/2019/Nahom Tesfaye
The DRC Prime Minister and Anuradha Gupta of GAVI, the Vaccine Alliance, toured the new health center and saw a vaccination demonstration. Created in 2000, GAVI brings together public and private sectors with the shared goal of creating equal access to new and underused vaccines for children living in the world’s poorest countries. The United States is one of its original six donor countries and contributes to GAVI through direct contributions. USAID has pledged $1 billion over the next three years to GAVI, pending Congressional approval, in support of GAVI's global plan to immunize 300 million additional children and save at least 5 million lives by 2020.
Le Premier Ministre de la RDC et Anuradha Gupta de GAVI, Alliance mondiale pour les vaccins, ont fait le tour du nouveau centre de santé et ont vu une séance de vaccination. Créé en 2000, GAVI met ensemble les secteurs public et privé avec l’objectif commun de créer un accès équitable aux nouveaux vaccins peu utilisés pour les enfants vivant dans les plus pays pauvres. Les Etats-Unis sont l’un des six pays donateurs et contribuent à GAVI à travers des contributions directes. L’USAID a promis plus de 1 milliards de dollars pour les trois prochaines années à GAVI, moyennant l’approbation du Congrès, en appui au plan global de GAVI pour vacciner 300 millions d’enfants supplémentaires et sauver au moins 5 millions de vies d’ici 2020.
Photo by Kaukab Jhumra Smith/USAID
Raw sewage overflow in the streets of Lucknow, Uttar Pradesh..India has been engaged in a campaign to eradicate polio in India which target the high-risk area of Uttar Pradesh and Bihar with polio immunization drives every 2 months. (photo Jean-Marc Giboux)
Nasra Mohammed Sherifwith her 7 months child - Siham Mohammed after getting polio vaccine at Togwajale Health Center, Jigjiga, Somali Regional State ©UNICEF Ethiopia/2019/Nahom Tesfaye
Adanech Andebo, carrying her Baby – Elizabeth Ikabo with her son Isaac Ikabo (blue top) and neighbours child Yohannes Lemma (red top) during the October 2010 mealses and polio vaccination campaign. Moto Village, Dale District, SNNPR Isaacs finger is being marked to show that he has received his vaccinations.
©UNICEF Ethiopia/2010/Getachew
Photo Credit: Allan Gichigi/MCSP
Dr Paul Odili of USAID/MCSP with Joseph Nakopir, Sub-County Health services coordinator, stands next to a bilboard that was supported by USAID/MCSP program
A young family sits beneath a sign encouraging childhood vaccination at the Bo District Hospital in Bo, Sierra Leone, in advance of a distribution by the United Methodist Church's Imagine No Malaria campaign. Photo by Mike DuBose, UMNS.
Area: Chandnmari Juggi, Vijaynagar District: Ghaziabad, State: Uttar Pradesh Country: India, 22nd March 2017 .
An ANM (Auxiliary Nurse Midwife) administers polio drops and vaccination to pregnant women and children at an Angnawadi in the Chandmari Juggi. 27-year-old Naazma Begum along with her husband Mohhammed Avrakh reside in a 100 sq.feet plot of land covered by blue and yellow plastic supported by bamboo sticks. In order to survive Naazma picks rags from garbage dumps and construction sites, sometimes travelling around 8 to 10 kilometers a day. Typically her day starts at 4:00 am, and sometimes can extend till late evenings. After picking useful items out of garbage she comes back to her slum colony and sorts out the various pieces of junk collected. Plastic, metals, glass and other items are separated and sold. Children, young and old participate in this activity. The sorted items would then be sold to a “Kabadi Wala” ( Wholesale Junk Shop).
On certain days Naazma does not go for her morning rounds of rag picking. This does affects her household economically. Her husband a magician doing shows for a living does not have a steady stream of income. In spite of the circumstances Naazma on these mornings goes house to house motivating young mothers from her community to take their children for routine immunization sessions organized in her locality by the National Health Mission.
An inspiration to many, Naazma sometimes has tough time convincing her friends to take their children. Excuses ranging from, “We don’t have time’, “the child will get fever “ are common in her community. Naazma patiently explains the dangers caused due to lack of vaccination and its necessity in today’s life to every household. Her effort along with the support of Community Mobilization Coordinator and Block Mobilization Coordinator has led to a massive increase in the children immunized in Vijaynagar Ghaziabad.
Title / Titre :
A young boy receives immunization vaccines /
Jeune garçon recevant un vaccin
Creator(s) / Créateur(s) : Photo Features Ltd.
Date(s) : 1959
Reference No. / Numéro de référence : ITEM 4949628, 4952101
central.bac-lac.gc.ca/.redirect?app=fonandcol&id=4949...
central.bac-lac.gc.ca/.redirect?app=fonandcol&id=4952...
Location / Lieu : Unknown / Inconnu
Credit / Mention de source :
Photo Features Ltd. National Film Board of Canada. Still Photography Division. Library and Archives Canada, e011177050 /
Photo Features Ltd. Office national du film du Canada. Service de la photographie. Bibliothèque et Archives Canada, e011177050
Ms. Oyunchimeg then administered a measles and rubella vaccine to P. Otgonjargal. “I love to travel to rural areas,” Ms. Oyunchimeg said. “It is both rewarding and fun to help people here.” © UNICEF/NYHQ2012-1732/BRIAN SOKOL